PointState Capital’s Kite Pharma, Inc. KITE Stock Holding History

PointState Capital’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-192,500	Closed	-$11.1M	–	160
2014 Q4	$11.1M	Buy	192,500 +167,500	+670%	+$7.05M	0.19%	80
2014 Q3	$713K	Buy	+25,000	New	+$619K	0.01%	94

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

PointState Capital's KITE Position: Q1 2015 in Review

PointState Capital sold out of Kite Pharma, Inc. (KITE) in Q1 2015, closing a stake of 192,500 shares — an estimated $11.1M sold.

PointState Capital first reported a position in KITE in Q3 2014 and held it in 2 quarters. The position peaked at $11.1M in Q4 2014. 148 funds tracked by Wall St. Rank hold KITE as of Q1 2015.

PointState Capital reported no remaining Kite Pharma, Inc. position as of Q1 2015 after selling out during the quarter.
PointState Capital sold 192,500 Kite Pharma, Inc. shares in Q1 2015, an estimated $11.1M.
PointState Capital first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 2 quarters.
PointState Capital's Kite Pharma, Inc. position peaked at $11.1M in Q4 2014.
148 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2015.

Based on PointState Capital's 13F filing for Q1 2015, filed 15 May 2015.